Form 4: Werewolf Therapeutics Director Sells Shares Via 10b5-1 Plan

Luke Evnin, a Director at Werewolf Therapeutics, Inc., reported the sale of common stock totaling 71,054 shares over three days in January 2026, executed under a pre-established 10b5-1 trading plan.

Summary

• Luke Evnin, a Director of Werewolf Therapeutics, Inc. (HOWL), reported sales of common stock.
• Transactions occurred on January 5, 6, and 7, 2026.
• A total of 71,054 shares were sold across these three dates.
• The sales were executed pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• The shares were sold at weighted average prices ranging from $0.64 to $0.65 per share.
• Following these transactions, the beneficial ownership of common stock indirectly held by entities associated with Mr. Evnin decreased from 2,453,919 shares to 2,401,243 shares.
• Mr. Evnin disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director reducing their stake, even though the sales were pre-planned under a 10b5-1 plan. While not an immediate red flag, it doesn't signal strong insider confidence.

Negatives

• A Director, Luke Evnin, reduced his indirect beneficial ownership in Werewolf Therapeutics by selling 71,054 shares.
• The sales occurred at relatively low prices, ranging from $0.63435 to $0.6599 per share.

Risks

• Insider selling, even under a 10b5-1 plan, can be perceived by the market as a lack of confidence in the company's future prospects by an informed individual.
• The reduction in beneficial ownership by a director could potentially lead to negative investor sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider trading reports like this Form 4 are common disclosures in the biotechnology and pharmaceutical industry, as executives and directors often hold significant equity stakes. While sales under a 10b5-1 plan are pre-scheduled and aim to avoid accusations of trading on material non-public information, they are still closely watched by investors for signals regarding insider sentiment, especially in a sector known for high risk and reward.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal of reduced confidence, potentially leading to negative sentiment or downward pressure on the stock price.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Equity Securities